Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Manchester United PLC (MANU) vs Viatris Inc (VTRS) Price & Performance

Manchester United PLCTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Manchester United PLC vs Viatris Inc — how do they compare? Manchester United PLC trades at $20.62 (market cap $3.51B), while Viatris Inc trades at $17.58 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5.7× Manchester United PLC's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Viatris Inc for 57 Days on average.

MANUVTRS
Market Cap
$3.51B$20.03B
Volume
412,76914,109,977
Sector
MediaHealth
52-Week High
$24.19$18.27
52-Week Low
$15.20$9.74
Typical Hold Time
109 Days57 Days
Enterprise Value
$4.33B$32.15B
Dividend Yield
1.26%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Manchester United PLC

Manchester United (MANU) trades at $20.25, down 0.74% on the day, with a bearish technical signal from moving averages. The company reported fiscal 2026 revenue of $678 million but continues to post net losses, with a -6.34% net income margin. Analyst consensus shows 40% buy ratings versus 60% hold, reflecting cautious optimism about the club's operational recovery and Champions League return despite persistent profitability challenges.

The stock presents a valuation opportunity with a market cap discount to Forbes' $7.2 billion franchise estimate, but faces significant execution risks including sustained losses, high debt levels, and competitive Premier League dynamics. Upside depends on cost management and revenue growth from European competition, while downside risks include continued negative cash flow and league-wide financial pressures.

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MANU
100% Buy0% Sell
Avg holding period · 109 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Manchester United PLC

Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.

Read more on MANU →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →